Cover Image
市場調查報告書

製藥產業上季度交易分析:聯盟、許可證、投資、M&A與趨勢

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2016

出版商 GlobalData 商品編碼 242636
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
Back to Top
製藥產業上季度交易分析:聯盟、許可證、投資、M&A與趨勢 Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2016
出版日期: 2016年08月04日 內容資訊: 英文 133 Pages
簡介

本報告提供全球製藥、醫療市場相關資料每季相關調查分析,尤其是以聯盟、許可證、M&A、資金籌措相關主要資料與趨勢分析為焦點,提供過去5季交易數量交易類型/市場區隔/各地區比較與交易額,製藥、醫療產業的主要創業投資(VC)和顧問公司最新資訊,為您概述為以下內容。

第1章 目錄

第2章 全球製藥、醫療市場:交易摘要

  • M&A
  • 股票上市交易
  • 創業投資交易
  • 私募股權的發行

第3章 全球製藥、醫療市場:聯盟交易

  • 聯盟交易
  • 聯盟交易:各治療領域
  • 聯盟交易:預付款/階段性付款、各交易金額
  • 聯盟交易:各治療領域,預付款/階段性付款、各交易金額
  • 聯盟交易:各階段,交易數量、交易額
  • 聯盟交易:各階段,預付款/階段性付款、各交易金額

第4章 全球製藥、醫療市場:授權合約

  • 授權合約
  • 授權合約交易:預付款/階段性付款、交易額
  • 授權合約交易:各治療領域,總交易額
  • 授權合約交易:各治療領域,預付款vs.階段性付款
  • 授權合約交易:各階段,總交易額
  • 授權合約交易:各階段,預付款vs.階段性付款

第5章 全球製藥、醫療市場:M&A財務分析

  • 平均交易額vs.中間交易額
  • 被收購企業的平均股票價格收益
  • 被收購企業的平均EV/EBITA
  • 每項營業利益的平均交易額
  • 每股的平均交易額vs.每股的平均市場價格
  • 每股的平均交易額vs.每股的平均賬面價格
  • 每銷售的平均交易額

第6章 全球製藥、醫療市場:交易摘要(各治療領域)

  • 腫瘤
  • 中樞神經系統
  • 感染疾病
  • 免疫系
  • 代謝障礙
  • 心血管系統
  • 消化管
  • 皮膚科
  • 呼吸系統
  • 眼科

第7章 交易摘要(各地區)

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 全球製藥、醫療市場:主要的投資顧問公司

  • M&A:過去1年
  • 股票上市:過去1年

第9章 附錄

第10章 其他資訊

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDPH0499QD

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2016" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2016

  • 2.1. Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2016
  • 2.2. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2016
  • 2.3. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2016
  • 2.4. Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2016
    • 2.4.1. Monsanto Receives Revised Acquisition Proposal from Bayer
    • 2.4.2. AbbVie Acquires Stemcentrx
    • 2.4.3. AbbVie to Raise USD7.8 Billion in Public Offering of Notes
    • 2.4.4. Mylan Prices Private Placement of Notes for USD6.5 Billion
    • 2.4.5. Pfizer Acquires Anacor Pharma for USD5.2 Billion

3. Pharmaceuticals & Healthcare, Global, Deals Summary, by Type

  • 3.1. Pharmaceuticals & Healthcare, Global, M&A, Q2 2016
    • 3.1.1. Top M&A Deals in Q2 2016
    • 3.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2015-Q2 2016
  • 3.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2016
    • 3.2.1. Top Initial Public Offerings in Q2 2016
    • 3.2.2. Top Secondary Offerings in Q2 2016
    • 3.2.3. Top PIPE Deals in Q2 2016
    • 3.2.4. Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2015-Q2 2016
    • 3.2.5. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2015-Q2 2016
  • 3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2016
    • 3.3.1. Top Venture Financing Deals in Q2 2016
    • 3.3.2. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2016
    • 3.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2016
    • 3.3.4. Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2015-Q2 2016
    • 3.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q2 2015-Q2 2016
    • 3.3.6. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2015-Q2 2016
  • 3.4. Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2016
    • 3.4.1. Top Private Equity Deals in Q2 2016
    • 3.4.2. Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2015-Q2 2016

4. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2016

  • 4.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2016
  • 4.2. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2015-Q2 2016
  • 4.3. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016
    • 4.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2016
    • 4.3.2. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2016
    • 4.3.3. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2016
  • 4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015-Q2 2016
  • 4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2015-Q2 2016
  • 4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2015-Q2 2016
  • 4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015-Q2 2016

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2016

  • 5.1. Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2016
  • 5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015-Q2 2016
    • 5.2.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2016
    • 5.2.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2016
    • 5.2.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2016
  • 5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2015-Q2 2016
  • 5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2015-Q2 2016
  • 5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2015-Q2 2016
  • 5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2015-Q2 2016
  • 5.7. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2015-Q2 2016

6. Pharmaceuticals & Healthcare, Global, M&A Financial Analysis

  • 6.1. Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q2 2015-Q2 2016
  • 6.2. Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q2 2015-Q2 2016
  • 6.3. Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2015-Q2 2016
  • 6.4. Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2015-Q2 2016
  • 6.5. Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q2 2015-Q2 2016
  • 6.6. Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2015-Q2 2016

7. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

  • 7.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2016
    • 7.1.1. Oncology-Deals of the Quarter
  • 7.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2016
    • 7.2.1. Central Nervous System-Deals of the Quarter
  • 7.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2016
    • 7.3.1. Infectious Disease-Deals of the Quarter
  • 7.4. Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2016
    • 7.4.1. Immunology-Deals of the Quarter
  • 7.5. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2016
    • 7.5.1. Metabolic Disorders-Deals of the Quarter
  • 7.6. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2016
    • 7.6.1. Cardiovascular-Deals of the Quarter
  • 7.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2016
    • 7.7.1. Gastrointestinal-Deals of the Quarter
  • 7.8. Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2016
    • 7.8.1. Ophthalmology-Deals of the Quarter
  • 7.9. Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2016
    • 7.9.1. Respiratory-Deals of the Quarter
  • 7.10. Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2016
    • 7.10.1. Dermatology-Deals of the Quarter

8. Deal Summary by Geography

  • 8.1. Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2016
    • 8.1.1. North America-Deals of the Quarter
  • 8.2. Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2016
    • 8.2.1. Europe-Deals of the Quarter
  • 8.3. Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2016
    • 8.3.1. Asia-Pacific-Deals of the Quarter
  • 8.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2016
    • 8.4.1. Rest of the World-Deals of the Quarter

9. Pharmaceuticals & Healthcare, Global, Top Advisors

  • 9.1. Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q2 2015-Q2 2016
  • 9.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q2 2015-Q2 2016

10. Appendix

11. Further Information

  • 11.1. Methodology
  • 11.2. About GlobalData
  • 11.3. Disclosure information
  • 11.4. Disclaimer

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2015 - Q2 2016
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2016
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2016
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2016
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2015 - Q2 2016
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2015 - Q2 2016
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2016
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2016
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2016
  • Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2015-Q2 2016
  • Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2015 - Q2 2016
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2016
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2016
  • Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2015 - Q2 2016
  • Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2015 - Q2 2016
  • Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2016
  • Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2015 - Q2 2016
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2016
  • Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2016
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2015 - Q2 2016
  • Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2016
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2016
  • Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2016
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2015 - Q2 2016
  • Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2015 - Q2 2016
  • Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2015 - Q2 2016
  • Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2015 - Q2 2016
  • Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2015 - Q2 2016
  • Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q2 2015 - Q2 2016
  • Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q2 2015 - Q2 2016
  • Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2015 - Q2 2016
  • Table 46: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 48: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 49: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 50: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 51: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 52: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 53: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 54: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 55: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 56: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 57: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 58: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 59: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 60: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 61: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Table 62: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q2 2015-Q2 2016

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2015 - Q2 2016
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q2 2016
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q2 2016
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q2 2015 - Q2 2016
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q2 2015 - Q2 2016
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q2 2015 - Q2 2016
  • Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q2 2016
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q2 2016
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2015 - Q2 2016
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2015 - Q2 2016
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2015 - Q2 2016
  • Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2015 - Q2 2016
  • Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q2 2015 - Q2 2016
  • Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2015 - Q2 2016
  • Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2015 - Q2 2016
  • Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2015 - Q2 2016
  • Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2015 - Q2 2016
  • Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q2 2015 - Q2 2016
  • Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2015 - Q2 2016
  • Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 42: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
  • Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2015 - Q2 2016
Back to Top